Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173548 · ClinicalTrials.gov registry record · Phase 2
Interleukin-1 Blockade in HF With Preserved EF
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT02173548 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 31 participants.
The verdict
NCT02173548, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
* Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure * Standard treatment for heart failure, show less than ideal results in HFpEF * Evidence of systemic inflammation is common in all forms of heart failure, including HFpEF * The main hypothesis of this study is that systemic inflammation contributes to heart failure symptoms and exercise limitations in patients with HFpEF * The main objective is to treat patients with HFpEF and evidence of systemic inflammation with an anti-inflammatory drug targeting Interleukin-1 (or placebo) to determine effects on cardiovascular function
Interventions
- DRUG Placebo
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02173548
The ClinicalTrials.gov registry entry for NCT02173548 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02173548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02173548 about?
NCT02173548 is a clinical study titled "Interleukin-1 Blockade in HF With Preserved EF". * Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure * Standard treatment for heart failure, show less than ideal results in HFpEF * Evidence of systemic inflammation is common in all forms of heart failure, including HFpEF * The main hypothesis of this study is...
What is the current status of trial NCT02173548?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2014-09. Estimated completion is 2017-06-01.
What interventions are being tested in trial NCT02173548?
The interventions under investigation include: Placebo (DRUG), Anakinra (DRUG).
Who is sponsoring clinical trial NCT02173548?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.